A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Andecaliximab (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 04 Aug 2017 This trial has been completed in Spain (on 2017-07-21), according to European Clinical Trials Database
- 27 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.